Protective effect of Naoxintong capsule on kidney injury in spontaneously hypertensive rats

Abstract

Abstract:

AIM: To investigate the protective effect of Naoxintong capsule (NXTC) on kidney injury in spontaneously hypertensive rats. METHODS: Twenty-four female spontaneously hypertensive rats (SHR) were randomly divided into model group, Irbesartan group and NXTC group, while eight female normotensive Wistar-Kyoto rats (WKY) were blank group. Rats in each group were intragastricly administrated with corresponding drugs and saline in eight weeks. Non-invasive blood pressure (BP) measuring instrument monitored BP of each group rats in every two weeks. The serum levels of total creatinine (Cre), uric acid (UA), urea (Urea) and microalbumin (MALB) were measured. Kidney injury was evaluated with histopathologic examination by hematoxylin eosin (H&E) staining. Real-time RT-PCR was used to test the gene expression changes of Mb, Nox1 and Duox2 in each group. And the expression of Mb in kidney tissue was measured by Western blot. RESULTS:NXTC significantly decreased mean BP in SHR group. Serum levels of Cre, UA and MALB in NXTC group were significantly lower than those in the model group (All P<0.01). Kidney injure in NXTC group was decreased as compared with model group (P<0.01). NXTC significantly reversed not only the down-regulation expression of Mb, Nox1 and Duox2 genes (All P<0.01), but also Mb protein (P<0.01) in SHR group. CONCLUSION: NXTC can protect SHR rats from kidney injury at least partly via regulating Mb overexpression.

Key words: Naoxintong capsule, hypertension, kidney injury, Mb

CLC Number:

R965.2

YANG Xiaohu, LIAN Hong, YU Yang, YUE Yingxing, ZHANG Yong. Protective effect of Naoxintong capsule on kidney injury in spontaneously hypertensive rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 875-880.

References

［1］Jing L, Zhang J, Sun J, et al. Inhibition of extracellular signal--regulated kinases ameliorates hypertension-induced renal vascular remodeling in rat models［J］. Int J Mol Sci, 2011, 12(12): 8333-8346.
［2］Engler MM, Engler MB, Pierson DM, et al. Effects of docosahexaenoic acid on vascular pathology and reactivity in hypertension ［J］. Exp Biol Med, 2003, 228(3): 299-307.
［3］Luo WM, Kong J, Gong Y, et al. Tongxinluo protects against hypertensive kidney injury in spontaneously-hypertensive rats by inhibiting oxidative stress and activating forkhead box O1 signaling［J］. PLoS One, 2015, 10(12): e0145130.
［4］Wang JY, Gao YB, Zhang N, et al. Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy ［J］. Am J Physiol Renal Physiol, 2014, 306(5): F486-895.
［5］Zhang XY, Yang XP, Lin YH, et al. Anti-hypertensive effect of Lycium barbarum L. with down-regulated expression of renal endothelial lncRNA sONE in a rat model of salt-sensitive hypertension ［J］. Int J Clin Exp Pathol, 2015, 8(6): 6981-6987.
［6］Wang YQ, Yan XX, Mi SL, et al. Naoxintong attenuates ischaemia/reperfusion injury through inhibiting NLRP3 inflammasome activation［J］. J Cell Mol Med, 2017, 21(1): 4-12.
［7］Xue J, Zhang X, Zhang C, et al. Protective effect of Naoxintong against cerebral ischemia reperfusion injury in mice ［J］. J Ethnopharmacol, 2016, 182: 181-189.
［8］John HK, Jeffrey BH, John R, et al. A noninvasive computerized tail-cuff system for measuring blood pressure in mice ［J］. Hypertension, 1995, 25(5): 1111-1115.
［9］Palm F, Nordquist L. Renal oxidative stress, oxygenation, andhypertension ［J］. Am J Physiol Regul Integr Comp Physiol, 2011, 30: R1229-1241.
［10］Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD ［J］. Am J Kidney Dis, 2006, 48: 752-760.
［11］Liu ZZ, Mathia S, Pahlitzsch TM. Myoglobin facilitates angiotensin II induced constriction of renal afferent arterioles ［J］. Am J Physiol Renal Physiol, 2017.
［12］Sedeek M, Nasrallah R, Touyz RM, et al. NADPH oxidases, reactive oxygen species, and the kidney: friend and foe ［J］. J Am Soc Nephrol, 2013, 24(10): 1512-1518.
［13］Montezano AC, Touyz RM. Oxidative stress, noxs, and hypertension: experimental evidence and clinical controversies［J］. Ann Med, 2012, 44 Suppl 1: S2-16.

[1]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[2]	ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge. Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
[3]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[4]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[5]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[6]	WU Zhiyong, LIU Bingrong, LI Bin, TANG Rui. Value of red blood cell distribution width in predicting early poor neurologic improvement after intravenous thrombolysis in patients with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 307-314.
[7]	LIU Chun, WANG Meng, CHENG Hui, LI Qinglin. Mechanism of gambogenic acid inhibiting the proliferation of melanoma based on RNA-seq sequencing technology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 155-163.
[8]	LI Xinyu, HUANG Xin. State of clinical application of meloxicam [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 189-197.
[9]	LU Kepeng, LIU Caihong, BI Ying. Effect of prophylactic anticoagulation duration on venous thrombosis after total hip/knee arthroplasty [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1269-1274.
[10]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[11]	YANG Zhian, ZHAO Yan, HE Yao, LIU Weiying, YU Qin. Pyroptosis mediated renal injury caused by chronic intermittent hypoxia and the intervention effect of edaravone in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 10-18.
[12]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[13]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[14]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[15]	WANG Zhen, QUAN Haiyan, HONG Chenliang, YUAN Lijialong, QIN Xuping. Swimming improves renal function of diabetic mice by promoting autophagy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 632-638.